A four-year collaboration between government, industry and academia, the project addresses a key challenge for the pharmaceuticals industry; getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure access for patients. It will achieve this by developing advanced digital design techniques that that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.
Part of the Science and Technology Facilities Council, and located at Sci-Tech Daresbury in Cheshire, the Hartree Centre's world leading supercomputing facilities and expertise in Big Data analytics and computational chemistry will be applied to case studies, provided by the industrial pharmaceutical project partners, to achieve better design and predictive processes for innovative medicines.
Hartree Centre Business Development Manager for Life Sciences, Dr. Adrian Toland, stated: "The medicines industry is a major component of UK manufacturing sector with a turnover in excess of GBP 31 billion. The industry's sustainability and future growth will be enhanced by responding to drivers such as the increasing demand for personalised medicines.
"We are extremely excited to be working with our major industrial project partners, as they seek to make innovative and more sophisticated medicines available to patients quicker and more cost effectively. Big Data is an essential ingredient in the design and development of our society's next generation of medicines, taking time and money out of the innovation process. The Hartree Centre's world leading facilities and skills in data analytics and modelling are pivotal to the success of this project, which will secure the UK's position at the forefront of new drug development."
The ADDoPT project addresses a key challenge for the pharmaceutical industry; getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure access for patients. The collaboration will pursue this goal by developing and implementing advanced digital design techniques that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.
'Digital design' combines research insight and mechanistic modelling to provide links between raw materials, formulation, manufacturing processes and drug product quality. It spans all operations, processes and procedures during the development and manufacture of medicines, and their in vivo application.
Alison Clough, Acting Chief Executive of the Association of the British Pharmaceutical Industry, commented: "We welcome the Government's commitment to continuing to develop the UK's life sciences sector. This project will help to put the UK in a position to make innovative medicines available to UK patients more quickly by futureproofing our advanced pharmaceutical manufacturing sector. By reducing the risks associated with the manufacture of medicines we can provide the UK with a competitive advantage in a globally significant sector."
ADDoPT is a four-year collaboration between government, industry and academia. Led by Process Systems Enterprise and supported by the Medicines Manufacturing Industry Partnership (MMIP), it involves pharmaceutical companies Pfizer, GlaxoSmithKline, AstraZeneca and Bristol-Myers Squibb, as well as leading UK universities, research centres, and knowledge-driven technology SMEs.
MMIP is a partnership set up jointly by ABPI and the BioIndustry Association (BIA). BIA Chief Executive, Steve Bates, stated: "This is a great result for UK medicines manufacturing and I look forward to seeing the new technology being applied to biologics so that we can continue to address unmet patient need with the most innovatively designed and effective treatments possible."
ADDoPT builds on UK excellence in big data, mechanistic modelling, process optimisation and control to establish a highly competitive UK knowledge value supply chain for the pharmaceutical sector that will seek to: